Viracta is committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.
Viracta’s proprietary platform is a highly targeted combination therapy approach for virus-associated malignancies. Our initial focus is on cancers associated with the Epstein Barr Virus (EBV). We will also expand into additional applications to utilize this approach for a range of cancers and virus-associated diseases.
Our team possesses deep, cross-functional experience and longstanding commitment to develop new medicines to benefit patients.
Jim brings over 25 years of pharmaceutical research and management experience. He is a General Partner at Latterell Venture Partners. Jim held senior roles within the industry, including that of Chairman and founding CEO of Oncomed Pharmaceuticals; President of Roche Bioscience; Chief Scientific Officer and Senior Vice President of Research and Development for Centocor (Janssen); and as Commanding Officer and Director of the US Naval Medical Research and Development Command. Jim has been responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service. Jim holds a medical degree from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He has authored or co-authored over 140 publications.
A physician, surgeon, researcher, philanthropist and scientist, Dr. Soon-Shiong is one of the country’s leading biopharmaceutical innovators. One of his many notable achievements was the development of the drug Abraxane, which is approved for the treatment of metastatic breast cancer, lung cancer and advanced pancreatic cancer. Dr. Soon-Shiong currently serves as Chairman and CEO of NantWorks, an ecosystem of companies aiming to create a transformative global health information system and next-generation pharma development network. Under the NantWorks umbrella, Dr. Soon-Shiong also serves as Chairman and CEO of NantKwest [NASDAQ: NK], and Chairman and CEO of NantHealth [NASDAQ: NH]. Dr. Soon-Shiong was instrumental in the formation of Cancer Breakthroughs 2020, a comprehensive collaboration of researchers, insurers, academic institutions and pharmaceutical companies that seeks to accelerate the potential of combination immunotherapy in the treatment of cancer. Over the course of his career, Dr. Soon-Shiong has pioneered novel therapies for both diabetes and cancer. He has published over 100 scientific papers, and has issued over 230 patents worldwide for groundbreaking advancements spanning myriad fields of technology and medicine.
An over 30-year veteran of venture capital investing, Mr. Fleming has helped raise and manage six venture funds totaling more than $500 million and has served on the boards of 19 venture-backed companies. He served as the initial president and CEO of Triangle Pharmaceuticals (acquired by Gilead Sciences, Inc. [NASDAQ:GILD]), Actigen (now part ofCorixa/GlaxoSmithKline [NYSE:GSK]), GenQuest Corixa/GlaxoSmithKline [NYSE:GSK]), and CombiChem (acquired by DuPont [NYSE:DD]). Mr. Fleming was a founding board member of Arizeke Pharmaceuticals, Ciphergen Biosystems (now Vermillion, Inc. [NASDAQ:VRML]) and Ambit Biosciences (acquired by Daiichi Sankyo) Gryphon Therapeutics, and served on the boards of Acorda Therapeutics [NASDAQ: ACOR], and was a founding director of Nereus Pharmaceuticals. He earned his BA from Amherst College and his MBA from the UCLA Graduate School of Management.
Richard brings over 20 years of drug development experience. He currently serves as Senior Vice President of Clinical Development at MEI Pharma. As a hematologist and oncologist, Richard has held several executive positions in the pharmaceutical industry, including Chief Medical Officer at Denovo BioPharma, HemaQuest Pharmaceuticals, Novalar Pharmaceuticals, and Favrille. He also served as Medical Director of the Bone Marrow Transplant Center of Rush University Medical Center. Richard holds a medical degree from the French School of Medicine in Lebanon, a M.S. from the University Paris XI and a M.B.A. from the University of Washington in Seattle. He has authored or co-authored more than 125 manuscripts, book chapters and scientific publications.
In addition to his roles and accomplishments, described below, Ivor was founding Managing Partner with Forward Ventures.
Dr. Simon has served as President of Nantkwest since its inception, and currently also serves as a Director for Cue BioPharma (NASDAQ:CUE). He previously held various senior level executive and advisory positions at Roche Labs, F. Hoffmann-La Roche (VTX:ROG), Connetics Corp. (NASDAQ:CNCT), Immunomedics (NASDAQ:IMMU), Immusol, NorthSound Capital, and HealthPro BioVentures. He has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND and BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. He trained clinically in infectious diseases, anesthesiology and internal medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.
Ivor has been involved in the biotechnology industry since the founding of Hybridtech (acquired by Eli Lilly) and the founding of Idec Pharmaceuticals in 1986 (merged with Biogen). Since 1990, He has been instrumental in the formation of numerous successful public biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Genesys (merged with Somatix and acquired by Cell Genesys); LigoCyte (acquired by Takeda); Morphotek (acquired by Eisai); Syndax TargeGen (acquired by Sanofi-Aventis); and Triangle Pharmaceuticals (acquired by Gilead). Ivor was the Founding President and CEO of the Sidney Kimmel Cancer Center and served on the faculty of the medical school and cancer center of the University of California, San Diego. He received B.A. and M.D. degrees from the Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Ivor to a six-year term on the National Cancer Advisory Board.
As our Chief Medical Officer, Dr. Warren directs our translational and development programs. Over her career, she has been instrumental in transitioning immunotherapy candidates utilizing diverse platforms (small molecule, biologics, RNA and cellular approaches) into the clinic and successful new blockbuster therapies like Enbrel to market. Most recently, Dr. Warren served at Atara Biotherapeutics as Vice President in the targeted cytotoxic T-lymphocytes programs for oncology and autoimmunity. Prior to that she held senior director positions in development at Amgen, Gilead Science and Ionis Pharmaceuticals. Dr. Warren received her B.S. degree from Baylor University and her M.D degree from the University of Nebraska. She completed her Immunology fellowship at National Jewish Hospital.
With over 20 years’ experience, David has a track record of innovation in business development and senior management roles at biotech as well as large pharma companies. His deal-making experience exceeds $1 billion in transactions and encompasses major corporate partnerships, spin-outs, start-ups and financings. David has provided corporate development, partnering, investment and Orphan drug commercialization advisory services to a range of organizations. In his consulting role with Novimmune, David repositioned the company for a major financing. David co-founded Kinagen, where he served as President, CEO. David also served as Vice President of Business Development for Ionis Pharmaceuticals and in senior roles at Rhone-Poulenc Rorer and Aventis Pharma. David received an M.B.A. from the Monterey Institute for International Studies, and Psychology and Molecular Biology degrees from California State University.
Prior to joining Viracta, Robert conducted Business Development for a global clinical research organization, working closely with many biotech organizations. Robert’s experience includes roles in clinical operations and management of global clinical trials in rare disease and immunology related indications across all phases of development. Robert also conducted molecular biology and microbiology research at Wright State University and was the recipient of a fellowship from The Oak Ridge Institute for Science Education in areas of biodefense interest with The United States Air Force Research Laboratory.
Douglas served as Director of Boston University Medical School’s Cancer Center and Vice-Chairman of the Division of Medicine. He was the scientific founder for HemaQuest Pharmaceuticals, and has served as an advisor to multiple biotech and pharmaceutical companies. His study of herpesviruses and their viral activation is preeminent in the field of hematology and oncology.
Professor and Director of the Lymphoma Program at Stanford University School of Medicine; Associate Director of Translational Science for the Stanford Cancer Institute; former Chief of the Stanford Division of Medical Oncology; member of the National Academy of Medicine and the National Academy of Sciences.
Director of the Hematologic Malignancies and Hematopoietic Stem Cell Transplantation Division in the Department of Medical Oncology for Sidney Kimmel Cancer Center at Thomas Jefferson University.
Professor and Head of the Lymphoma Program at Ohio State University, and member of Blood and Marrow Transplant Clinical Trials Network.
Director of the Ivy Center for Advanced Brain Tumor Treatment in Seattle; pioneered the concept of the potential role of cytomegalovirus in cancer pathogenesis and therapy, and a leader in development of systems biology approaches to cancer therapy, especially by targeting molecular hubs of disease and immunotherapy targets.
Chief Medical Officer at Infectious Disease Research Institute (IDRI), and Co-Director of University of Washington/Fred Hutch Center for AIDS Research.
Professor of Microbiology at Penn Institute for Immunology at University of Pennsylvania bringing expertise in viral models of immune responses, epigenetics and T cell exhaustion.